Lipoprotein(a) Does Not Predict Thrombotic Events and In-Hospital Outcomes in Patients with COVID-19
-
Published:2023-05-18
Issue:10
Volume:12
Page:3543
-
ISSN:2077-0383
-
Container-title:Journal of Clinical Medicine
-
language:en
-
Short-container-title:JCM
Author:
Bianconi Vanessa1, Mannarino Massimo R.2ORCID, Ramondino Federica1, Fusaro Jessica1, Giglioni Francesco1, Braca Marco1, Ricciutelli Federica1, Lombardini Rita1ORCID, Paltriccia Rita1, Greco Alessia1, Lega Iliana C.2, Pirro Matteo1
Affiliation:
1. Unit of Internal Medicine, Department of Medicine and Surgery, University of Perugia, 06129 Perugia, Italy 2. Women’s College Research Institute, Women’s College Hospital, Toronto, ON M5G 1N8, Canada
Abstract
The prothrombotic and proinflammatory properties of lipoprotein(a) (Lp(a)) have been hypothesized to play a role in the pathogenesis of severe COVID-19; however, the prognostic impact of Lp(a) on the clinical course of COVID-19 remains controversial. This study aimed to investigate whether Lp(a) may be associated with biomarkers of thrombo-inflammation and the occurrence of thrombotic events or adverse clinical outcomes in patients hospitalized for COVID-19. We consecutively enrolled a cohort of patients hospitalized for COVID-19 and collected blood samples for Lp(a) assessment at hospital admission. A prothrombotic state was evaluated through D-dimer levels, whereas a proinflammatory state was evaluated through C-reactive protein (CRP), procalcitonin, and white blood cell (WBC) levels. Thrombotic events were marked by the diagnosis of deep or superficial vein thrombosis (DVT or SVT), pulmonary embolism (PE), stroke, transient ischemic attack (TIA), acute coronary syndrome (ACS), and critical limb ischemia (CLI). The composite clinical end point of intensive care unit (ICU) admission/in-hospital death was used to evaluate adverse clinical outcomes. Among 564 patients (290 (51%) men, mean age of 74 ± 17 years) the median Lp(a) value at hospital admission was 13 (10–27) mg/dL. During hospitalization, 64 (11%) patients were diagnosed with at least one thrombotic event and 83 (15%) patients met the composite clinical end point. Lp(a), as either a continuous or categorical variable, was not associated with D-dimer, CRP, procalcitonin, and WBC levels (p > 0.05 for all correlation analyses). In addition, Lp(a) was not associated with a risk of thrombotic events (p > 0.05 for multi-adjusted odds ratios) nor with a risk of adverse clinical outcomes (p > 0.05 for multi-adjusted hazard ratios). In conclusion, Lp(a) does not influence biomarkers of plasma thrombotic activity and systemic inflammation nor has any impact on thrombotic events and adverse clinical outcomes in patients hospitalized for COVID-19.
Funder
Fondazione Cassa di Risparmio di Perugia
Reference54 articles.
1. (2023, March 01). WHO Coronavirus (COVID-19) Dashboard. Available online: https://covid19.who.int/. 2. Global impact of the first year of COVID-19 vaccination: A mathematical modelling study;Watson;Lancet Infect. Dis.,2022 3. Impact of low vaccine coverage on the resurgence of COVID-19 in Central and Eastern Europe;Fan;One Health,2022 4. Rahman, M.S., Harun, M.G.D., Sumon, S.A., Mohona, T.M., Abdullah, S.A.H.M., Khan, M.N.H., Gazi, M.I., Islam, M.S., and Anwar, M.M.U. (2022). Hospitalization and Mortality by Vaccination Status among COVID-19 Patients Aged ≥ 25 Years in Bangladesh: Results from a Multicenter Cross-Sectional Study. Vaccines, 10. 5. COVID-19-Associated Hospitalizations Among Vaccinated and Unvaccinated Adults 18 Years or Older in 13 US States, January 2021 to April 2022;Havers;JAMA Intern. Med.,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|